TRIM2 held predictive power for DMFS in all patients receiving chemotherapy (p < 0.05, Supplementary Figure S6e), particularly in TNBC (p < 0.05, Figure 3e) and ER-negative tumours (p < 0.01, Supplementary Figure S8). This evidence concerns the gene TRIM2 and neoplasm.